{"id":"https://openalex.org/W3010635903","doi":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","title":"Abstract OT1-01-02: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer","display_name":"Abstract OT1-01-02: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer","publication_year":2020,"publication_date":"2020-02-15","ids":{"openalex":"https://openalex.org/W3010635903","doi":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","mag":"3010635903"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs19-ot1-01-02","doi":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064069772","display_name":"Harry D. Bear","orcid":"https://orcid.org/0000-0002-7632-9019","observed_orcids":["https://orcid.org/0000-0002-7632-9019"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry Douglas Bear","raw_affiliation_strings":["Virginia Commonwealth University, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University, Richmond, VA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020110586","display_name":"Michael O. Idowu","orcid":"https://orcid.org/0000-0002-7416-5444","observed_orcids":["https://orcid.org/0000-0002-7416-5444"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael O. Idowu","raw_affiliation_strings":["Virginia Commonwealth University, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University, Richmond, VA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080982053","display_name":"Andrew Stewart Poklepovic","orcid":"https://orcid.org/0000-0002-4015-5037","observed_orcids":["https://orcid.org/0000-0002-4015-5037"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Poklepovic","raw_affiliation_strings":["Virginia Commonwealth University, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University, Richmond, VA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035179840","display_name":"Adam P. Sima","orcid":"https://orcid.org/0000-0001-8426-9987","observed_orcids":["https://orcid.org/0000-0001-8426-9987"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Sima","raw_affiliation_strings":["Virginia Commonwealth University, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University, Richmond, VA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074048193","display_name":"Maciej Kmieciak","orcid":"https://orcid.org/0000-0002-0889-5529","observed_orcids":["https://orcid.org/0000-0002-0889-5529"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maciej Kmieciak","raw_affiliation_strings":["Virginia Commonwealth University, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University, Richmond, VA","institution_ids":["https://openalex.org/I184840846"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I184840846"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"4_Supplement","first_page":"OT1","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6532999873161316,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6532999873161316,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.30219998955726624,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9819999933242798},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":1.0},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.8040000200271606},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9470000267028809},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9070000052452087},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8389999866485596},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.9160000085830688},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7519999742507935},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.7649999856948853},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.765999972820282},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7870000004768372},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.7440000176429749},{"id":"https://openalex.org/keywords/immune-microenvironment","display_name":"immune microenvironment","score":0.4560000002384186},{"id":"https://openalex.org/keywords/mhc-class-i-expression","display_name":"MHC class I expression","score":0.6230000257492065},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9070000052452087}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8546557426452637},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.734394907951355},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7166587710380554},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6637962460517883},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6489729285240173},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5861522555351257},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.583278477191925},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5460595488548279},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.4718211591243744},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4652211666107178},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.4290424585342407},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.11388501524925232},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0952264666557312},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs19-ot1-01-02","doi":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4396590487","https://openalex.org/W4408043328","https://openalex.org/W3013417770","https://openalex.org/W4379285903","https://openalex.org/W2806692351","https://openalex.org/W7162517742","https://openalex.org/W2793525366","https://openalex.org/W2621592748","https://openalex.org/W2588727366","https://openalex.org/W3006092718"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Higher":[2],"levels":[3],"of":[4,16,53,62,73,110,173,203,210,287,326,333,372,385,441,528],"tumor-infiltrating":[5],"lymphocytes":[6],"(TIL)":[7],"in":[8,189,222,303,339,360,391,406],"breast":[9,79,87,240,330],"cancers":[10,35],"are":[11,90,125],"associated":[12],"with":[13,85,328,336,446],"increased":[14],"likelihood":[15],"pathologic":[17],"complete":[18],"response":[19],"(pCR)":[20],"to":[21,34,118,130,138,292,382,387,397,435,456,474],"chemotherapy":[22,94,245,519],"and":[23,46,51,59,134,186,195,205,322,343,349,438,443,459,463],"improved":[24],"outcomes.":[25],"DNA":[26],"methyltransferase":[27],"inhibitors":[28],"(DNMTi)":[29],"can":[30,175],"augment":[31],"immune":[32,214],"responses":[33],"by":[36,107,149,162,307,516],"upregulating":[37],"tumor":[38,442],"antigen":[39,47],"expression,":[40],"increasing":[41,60],"MHC":[42],"Class":[43],"I":[44],"expression":[45,316,335],"presentation,":[48],"decreasing":[49],"numbers":[50],"activity":[52],"myeloid":[54],"derived":[55],"suppressor":[56],"cells":[57],"(MDSC)":[58],"responsiveness":[61],"T":[63],"lymphocytes.":[64,448],"We":[65],"have":[66,197,468],"shown":[67],"that":[68,388,395],"decitabine":[69,97,204,514],"augments":[70],"the":[71,131,168,171,190,230,296,356,392,418,489,529],"effectiveness":[72],"immunotherapy":[74,133,185],"against":[75],"murine":[76],"triple":[77],"negative":[78,271],"cancer":[80,88,331,524],"(TNBC).":[81],"Trial":[82],"design:":[83],"Patients":[84],"HER-2-negative":[86],"who":[89,196],"candidates":[91,242],"for":[92,243,295,422,520],"neoadjuvant":[93,120,244,518],"will":[95,219,379,411,432,452],"receive":[96],"(15":[98],"mg/kg":[99],"x":[100],"4":[101,147,160],"doses":[102,109,202],"over":[103],"5":[104],"days)":[105],"followed":[106,148,161,515],"2":[108,114],"pembrolizumab":[111,512],"(200":[112],"mg,":[113],"weeks":[115],"apart)":[116],"prior":[117,129,137,473],"starting":[119,139],"chemotherapy.":[121,140],"Two":[122],"research":[123],"biopsies":[124],"obtained":[126],"-":[127,144,157,306],"1":[128,135,208,471],"window":[132,345],"afterwards,":[136],"Chemotherapy":[141],"regimens:":[142],"TNBC":[143,248],"ddAC":[145,158],"X":[146,154,159,165],"weekly":[150,163],"Taxol":[151,164],"+":[152,513],"Carboplatin":[153],"12;":[155],"HR+":[156],"12.":[166],"After":[167],"safely":[169],"lead-in,":[170],"sequence":[172],"regimens":[174],"be":[176,220,380,412,433,453],"reversed,":[177],"per":[178],"treating":[179],"physician":[180],"preference.":[181],"Safety":[182],"Lead-In:":[183],"During":[184],"dose-dense":[187],"AC":[188],"first":[191],"11":[192,479],"patients":[193,327],"enrolled":[194],"received":[198],"at":[199,206,401,414],"least":[200,207],"3":[201],"dose":[209],"pembrolizumab,":[211],"clinically":[212],"significant":[213],"related":[215],"adverse":[216],"events":[217],"(irAEs)":[218],"reported":[221],"an":[223],"expedited":[224],"manner.":[225],"Accrual":[226],"was":[227,234],"halted":[228],"until":[229],"safety":[231,481],"lead-in":[232,482],"phase":[233],"completed.":[235,485],"Brief":[236],"Eligibility":[237],"criteria:":[238],"Primary":[239,300],"cancer,":[241],"Cohort":[246,265,352,364,376,398,407,409],"A:":[247],"(ER<10%,":[249],"PR<10%,":[250],"Her-2":[251,270],"negative)":[252],"cT2,":[253,257,272],"N1":[254,273],"or":[255,263,268,274,278],"N2":[256,275],"3-5":[258],"cm,":[259],"N0":[260],"Any":[261,276],"T3":[262,277],"T4":[264],"B:":[266],"ER+":[267],"PR+,":[269],"T4ECOG":[279],"status":[280],"0-1":[281],"No":[282],"Active":[283],"autoimmune":[284],"diseases":[285],"Absence":[286],"metastatic":[288],"disease":[289],"too":[290],"extensive":[291],"consider":[293],"surgery":[294],"primary":[297,357],"Specific":[298],"aims:":[299],"endpoint:":[301],"Changes":[302],"Lymphocyte":[304],"infiltration":[305],"10-15%":[308],"Tumor":[309],"area":[310,312],"Stromal":[311],"Secondary":[313],"endpoints:":[314],"Gene":[315],"(Nanostring)":[317],"Multiplex":[318],"Cell":[319],"Markers":[320],"(DAPI/CD4/CD8/FOXP3/CK/PDL1/PDL2,":[321],"MDSCs)":[323],"pCR":[324,337],"Percentage":[325],"lymphocyte-predominant":[329],"Correlation":[332],"PD-L1":[334],"MDSC":[338],"blood":[340],"samples":[341],"pre-":[342],"post-":[344],"portion":[346],"Sample":[347],"Size":[348],"Statistical":[350],"methods:":[351],"A":[353,365,428,458],"(TNBC)":[354],"is":[355,425,494],"target":[358,464],"group":[359],"this":[361,423],"trial.":[362],"When":[363],"has":[366,483],"achieved":[367],"its":[368],"required":[369],"sample":[370,420,492],"size":[371,421,493],"28":[373],"evaluable":[374],"patients,":[375],"B":[377,399,410],"(HR+)":[378],"closed":[381],"accrual":[383,386,396,462],"irrespective":[384],"cohort.":[389],"However,":[390],"unlikely":[393],"event":[394],"occurs":[400],"a":[402],"faster":[403],"rate":[404],"than":[405],"A,":[408],"capped":[413],"18":[415],"patients.":[416,427,496],"Therefore,":[417],"projected":[419,490],"study":[424],"32-50":[426,495],"one-sided":[429],"paired":[430,450],"t-test":[431,451],"used":[434],"compare":[436],"baseline":[437],"post-treatment":[439],"percentage":[440],"stromal":[444],"areas":[445],"infiltrating":[447],"The":[449,478],"applied":[454],"separately":[455],"Cohorts":[457],"B.":[460],"Present":[461],"accrual:":[465],"12":[466],"subjects":[467],"been":[469,484],"accrued;":[470],"withdrew":[472],"any":[475],"protocol":[476],"therapy.":[477],"patient":[480],"As":[486],"described":[487],"above,":[488],"total":[491],"Citation":[497],"Format:":[498],"Harry":[499],"Douglas":[500],"Bear,":[501],"Michael":[502],"O.":[503],"Idowu,":[504],"Andrew":[505],"Poklepovic,":[506],"Adam":[507],"Sima,":[508],"Maciej":[509],"Kmieciak.":[510],"Neoadjuvant":[511],"standard":[517],"locally":[521],"advanced":[522],"HER2-breast":[523],"[abstract].":[525],"In:":[526],"Proceedings":[527],"2019":[530,536],"San":[531,539],"Antonio":[532],"Breast":[533],"Cancer":[534,545],"Symposium;":[535],"Dec":[537],"10-14;":[538],"Antonio,":[540],"TX.":[541],"Philadelphia":[542],"(PA):":[543],"AACR;":[544],"Res":[546],"2020;80(4":[547],"Suppl):Abstract":[548],"nr":[549],"OT1-01-02.":[550]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2020-03-13T00:00:00"}